Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
CP
cision pr newswire
via Pr Newswire - Corroborated by 3 others
Updated 1h ago
Source Verification
Corroboration Score: 4This story was independently reported by 4 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
